Gilead strengthens ADC capabilities with $5bn Tubulis acquisition

CE2026-04-08T10:19:00

Source:

Deal expands the companies’ existing two-year partnership and builds Gilead’s oncology pipeline.

Gilead is acquiring German biotechnology company Tubulis for $3.15 billion upfront, bolstering its oncology pipeline with a suite of investigational, next-generation antibody-drug conjugates (ADCs).

This includes TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i)-targeting ADC for ovarian cancer and other solid tumours. The ADC candidate is currently

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member